## CVS: CVS Health Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.8% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge. Caution: declining volume (39% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($76.24)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 0)

**1. Canoe Financial LP Has $128.51 Million Stock Holdings in CVS Health Corporation $CVS**
- Source: MarketBeat | 20251226T100820 | Bullish | Relevance: 100%
- Canoe Financial LP has significantly increased its stake in CVS Health Corporation, now holding 1,704,608 shares valued at $128.51 million, representing 1.8% of its investment portfolio. Institutional investors collectively own 80.66% of CVS Health, with major holdings from Vanguard, State Street, and Invesco. The stock has a "Moderate Buy" consensus rating from analysts, with a target price of $94.67, and recently beat earnings and revenue expectations.

**2. CVS Health's (NYSE:CVS) investors will be pleased with their notable 84% return over the last year**
- Source: Yahoo Finance | 20251224T130807 | Bullish | Relevance: 100%
- CVS Health Corporation (NYSE:CVS) shareholders have seen an 84% total shareholder return (TSR) in the last year, outperforming the market's 14% return. While the share price alone is up 76%, the substantial dividend payments explain the even higher TSR. Despite a 91% drop in EPS, revenue growth of 6.7% and insider buying activity suggest underlying business development.

**3. Yousif Capital Management LLC Lowers Stock Position in CVS Health Corporation $CVS**
- Source: MarketBeat | 20251224T040838 | Somewhat-Bullish | Relevance: 100%
- Yousif Capital Management LLC reduced its stake in CVS Health Corporation by 5.7% in the third quarter, selling 12,896 shares. Despite this, several other large institutional investors, including Vanguard, State Street, and Invesco, increased their positions, with Norges Bank acquiring a significant new stake. CVS Health reported strong Q3 earnings, beating analyst estimates, and has a consensus "Moderate Buy" rating with a price target of $94.67.

**4. Q3 Rundown: Cencora (NYSE:COR) Vs Other Health Insurance Providers Stocks**
- Source: Finviz | 20251224T223600 | Neutral | Relevance: 75%
- This article reviews the Q3 earnings of several health insurance providers, focusing on Cencora (NYSE:COR) and comparing its performance with competitors like CVS Health (NYSE:CVS), Molina Healthcare (NYSE:MOH), UnitedHealth (NYSE:UNH), and Clover Health (NASDAQ:CLOV). It highlights industry trends, regulatory impacts, and the influence of AI while providing a snapshot of each company's revenue, EPS, and stock performance post-earnings.

**5. Is Walmart Open On Christmas Eve? Here's What To Know About The Retailer And Other Stores**
- Source: Blavity News | 20251224T020917 | Neutral | Relevance: 74%
- This article provides a comprehensive guide to the holiday operating hours for major retailers, grocery stores, convenience stores, and gas stations on Christmas Eve, Christmas Day, New Year's Eve, and New Year's Day. It details specific hours for stores like Walmart, Target, Costco, Kroger, and Albertsons, helping consumers plan their last-minute shopping during the festive season. The information is compiled from sources such as The Associated Press, Good Morning America, and Taste of Home.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 10, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | JP Morgan | $101 | $93 | +9% |
| 2025-12-12 | Bernstein | $87 | $86 | +1% |
| 2025-12-10 | Truist Securiti | $98 | $95 | +3% |
| 2025-12-10 | Piper Sandler | $101 | $99 | +2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | JP Morgan | main | Overweight |
| 2025-12-12 | Bernstein | main | Market Perform |
| 2025-12-10 | Truist Securiti | main | Buy |
| 2025-12-10 | Piper Sandler | reit | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 11 ($1.40M) |
| Sells | 4 ($2.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 9.4% (-2.3%)
- Vanguard Group Inc: 9.4% (-1.3%)
- Dodge & Cox Inc.: 5.8% (-0.1%)
- JPMORGAN CHASE & CO: 5.6% (+162.5%)
- Capital World Invest: 5.4% (+2.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 10 raises (avg +6%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.7% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.56 indicates undervaluation relative to growth. Analyst sentiment positive (10 raises, avg +6%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $101.1B |
| Beta | 0.48 |
| 52W Range | $43.65 - $85.15 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.56 |
| Forward P/E | 11.1 |
| Current P/E | 12.0 |
| YoY Growth | 7.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.9% to 0.8% (+1.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.2pp (needs >4.0% for momentum thesis). MRS_5 at 0.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 55. Volume at 39% of 20MA suggests lack of conviction. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.77% (CS: 62) | Neutral |
| RSI_14 | 55.2 | Neutral |
| MACD Histogram | 0.12 | Bullish |
| vs SMA20 | 1.017x | Above |
| vs SMA50 | 1.007x | Above |
| vs SMA200 | 1.126x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $79.58
- **Stop Loss:** $76.24 (4.2% risk)
- **Target:** $82.92 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 395
- **Position Value:** $31,434.10
- **Portfolio %:** 31.43%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-11 (Est: $0.96)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.36 | $1.60 | +17.9% |
| 2025Q2 | $1.46 | $1.81 | +23.8% |
| 2025Q1 | $1.67 | $2.25 | +34.5% |
| 2024Q4 | $0.92 | $1.19 | +29.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*